Twenty-two people, including two ophthalmologists and ten opticians, will stand trial in Paris in the spring of 2027 in a case of alleged organized fraud targeting supplemental health insurance companies. Fifteen legal entities are also being sent to trial, including five ophthalmology centers. The investigation, opened in 2025 following reports from insurance companies, uncovered a system that allegedly embezzled approximately €12 million per year since 2023. Eleven defendants have been placed under judicial supervision, some with a ban on managing a company or presiding over an association.
According to the investigation, the scheme relied on cooperation between certain insured individuals, opticians, and prescribers to obtain reimbursements from supplemental health insurance companies exceeding their actual expenses. Clients were allegedly directed to ophthalmologists who sometimes issued prescriptions without a prior examination. The invoices then allowed for maximum coverage, which was converted into store credit. Clients could thus purchase high-end frames, sunglasses, or other eyewear, while some products billed to supplemental insurers were reportedly kept in stock. Opticians reportedly admitted that more than half of their revenue came from this system.
The damage could extend far beyond the single case being judged.
Investigators suspect a much larger fraud than that directly targeted by the proceedings. Across the entire Parisian optical market, similar practices could represent up to €250 million since 2023, according to an estimate provided by the gendarmerie. However, this amount does not yet constitute legally established damages in the case referred to the court. Searches conducted between January and July 2026 in stores, offices, and health centers led to the seizure of optical equipment valued at €1,3 million.
The trial is scheduled to take place from June 3 to 15, 2027. The defendants face up to ten years in prison, as well as the confiscation of certain assets. The case could also have administrative and professional consequences independent of the criminal proceedings: tax adjustments, potential deregistration of the doctors involved by the national health insurance system, or disciplinary proceedings before the Medical Council. More broadly, the case raises the issue of reimbursement control in a sector where the proliferation of health centers, third-party payment systems, and the complexity of supplemental insurance contracts can create loopholes exploited by organized networks.








